Semaglutide does not directly increase the risk of blood clots, but it does affect blood sugar and metabolism, which can indirectly impact the heart and blood vessels
Among participants with obesity but without diabetes, tirzepatide was superior to semaglutide for both body weight reduction and waist circumference reduction at 72 weeks
These numbers are precise, calculated using the formula: dose (mg) divided by 17 (mg/mL) equals volume (mL)
Quick Facts Semaglutide doses, such as 2.5 mg, are measured in milligrams (mg)
Conclusion Semaglutide and Tirzepatide treatment options are present as a significant advance in the field of weight management and type 2 diabetes management
Tirzepatide is a dual GIP/GLP-1 receptor agonist with a 5-day half-life, meaning it takes approximately 25 days (3-4 weeks) for the medication to be substantially eliminated from your body after your final injection